PRA Health Sciences, Inc. (PRAH): Price and Financial Metrics

PRA Health Sciences, Inc. (PRAH)

Today's Latest Price: $121.86 USD

6.31 (-4.92%)

Updated Jan 27 4:00pm

Add PRAH to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 64 in Medical - Diagnostics/Research

See all "A" rated Strong Buy stocks

PRAH Stock Summary

  • PRAH has a market capitalization of $8,222,057,564 -- more than approximately 80.69% of US stocks.
  • PRA Health Sciences Inc's stock had its IPO on November 14, 2014, making it an older stock than just 21.57% of US equities in our set.
  • The volatility of PRA Health Sciences Inc's share price is greater than that of merely 21.79% US stocks with at least 200 days of trading history.
  • Stocks that are quantitatively similar to PRAH, based on their financial statements, market capitalization, and price volatility, are WMS, EXLS, TTEK, CRL, and G.
  • PRAH's SEC filings can be seen here. And to visit PRA Health Sciences Inc's official web site, go to

PRAH Stock Price Chart Interactive Chart >

Price chart for PRAH

PRAH Price/Volume Stats

Current price $121.86 52-week high $137.88
Prev. close $128.17 52-week low $58.67
Day low $120.75 Volume 279,841
Day high $125.88 Avg. volume 291,688
50-day MA $120.41 Dividend yield N/A
200-day MA $105.51 Market Cap 7.82B

PRA Health Sciences, Inc. (PRAH) Company Bio

PRA Health Sciences provides various product development services for pharmaceutical and biotechnology companies worldwide. The company was founded in 1976 and is based in Raleigh, North Carolina.

PRAH Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$121.86$162.08 26%

We started the process of determining a valid price forecast for PRA Health Sciences Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that PRA Health Sciences Inc ranked in the 57th percentile in terms of potential gain offered. Moreover, under all the scenarios we modelled, the output consistently forecasted positive returns. The most interesting components of our discounted cash flow analysis for PRA Health Sciences Inc ended up being:

  • In the past 4.7 years, PRA Health Sciences Inc has a compound free cash flow growth rate of 0.28%; that's better than 62.74% of cash flow producing equities in the Healthcare sector, where it is classified.
  • PRA Health Sciences Inc's weighted average cost of capital (WACC) is 8%; for context, that number is higher than merely 24.81% of tickers in our DCF set.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

Want more companies with a valuation profile/forecast similar to that of PRA Health Sciences Inc? See HBIO, CHE, JAZZ, SNY, and UTHR.

PRAH Latest News Stream

Event/Time News Detail
Loading, please wait...

PRAH Latest Social Stream

Loading social stream, please wait...

View Full PRAH Social Stream

Latest PRAH News From Around the Web

Below are the latest news stories about PRA Health Sciences Inc that investors may wish to consider to help them evaluate PRAH as an investment opportunity.

The Daily Biotech Pulse: Fluidigm's Saliva-Based COVID Test Approved In Europe, China Backs Amarin's Vascepa

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 21) Acasti Pharma Inc (NASDAQ: ACST ) Alimera Sciences Inc (NASDAQ: ALIM ) argenx SE – ADR (NASDAQ: ARGX ) Axonics Modulation Technologies Inc (NASDAQ: AXNX ) AzurRx BioPharma Inc (NASDAQ: AZRX ) Chimerix Inc (NASDAQ: CMRX ) Edap Tms SA (NASDAQ: EDAP ) Eli Lilly And Co (NYSE: LLY ) (announced positive results for its COVID-19 antibody treatment) ESSA Pharma Inc (NASDAQ: EPIX ) Idera Pharmaceuticals Inc (NASDAQ: IDRA ) Inari Medical Inc (NASDAQ: NARI ) INmune Bio Inc (NASDAQ: INMB ) ( INSM ) Integra Lifesciences Holdings Corp (NASDAQ: IART ) Inventiva ADR Representing Ord Shs (NASDAQ: IVA ) Jounce Therapeutics Inc (NASDAQ: JNCE ) Krystal Biotech I...

Benzinga | January 22, 2021

The Daily Biotech Pulse: Bausch Health Issues Positive Pre-Announcement, Acorda Streamlines Operations

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 12) AbbVie Inc (NYSE: ABBV ) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Aldeyra Therapeutics Inc (NASDAQ: ALDX ) Alkermes Plc (NASDAQ: ALKS ) AtriCure Inc. (NASDAQ: ATRC ) Bioanalytical Systems, Inc. (NASDAQ: BASI ) BIOLASE Inc (NASDAQ: BIOL ) (announced an agreement to expand laser adoption and hands-on training programs in targeted geographies) CareDx Inc (NASDAQ: CDNA ) Celsius Holdings, Inc. (NASDAQ: CELH ) DermTech Inc (NASDAQ: DMTK ) Dyne Therapeutics Inc (NASDAQ: DYN ) Edap Tms SA (NASDAQ: EDAP ) Evelo Biosciences Inc (NASDAQ: EVLO ) EXACT Sciences Corporation (NASDAQ: EXAS ) Eyenovia Inc (NASDAQ: EYEN ) Genetron Holdings Ltd – ADR (NASDAQ...

Benzinga | January 13, 2021

Contract Research Organization Market to Witness Huge Growth by 2024| Key Players are IQVIA Holdings, Inc., Laboratory Corporation of America Holdings, Syneos Health Inc, PRA Health Sciences, Medpace Holdings Inc and Wuxi AppTec Co Ltd the exclusive leading provider of market research reports published research report on “China Contract Research Organization (CRO) Market (Clinical, Pre-clinical & Discovery): Insights, Trends and Forecast (2020-2024)”. China CRO market value is anticipated to reach US$27.04 billion in 2024, growing

OpenPR | January 11, 2021

Are These Medical Stocks Cruising Toward Bullish Gains? Here's A Key Sign

Medical stocks made a comeback in 2020. The best-performing among them include medical technology companies with high Composite Ratings, a key metric measuring growth.

Yahoo | January 7, 2021

PRA Health Sciences collaborates with PWNHealth and Fulgent Genetics to provide at-home COVID-19 test capabilities

PRA’s remote patient monitoring (RPM) solution now offers a suite of COVID-19 tools – diagnostic testing, clinical monitoring, and symptom reporting and management functionalityRALEIGH, N.C., Dec. 17, 2020 (GLOBE NEWSWIRE) -- PRA Health Sciences (NASDAQ: PRAH) announced today the enhancement of its COVID-19 Monitoring Program with the addition of at-home COVID-19 testing capabilities. Enabled through a collaboration with PWNHealth and Fulgent Genetics (NASDAQ: FLGT), the testing capabilities expand PRA’s existing COVID-19 clinical monitoring, symptom reporting and management services that are available on the patient-facing Health HarmonyTM mobile app. Patients are supported throughout their COVID-19 journey – from education, exposure, testing and monitoring through recovery. “Getting ...

Yahoo | December 17, 2020

Read More 'PRAH' Stories Here

PRAH Price Returns

1-mo 0.38%
3-mo 23.44%
6-mo 14.36%
1-year 17.86%
3-year 29.39%
5-year 182.87%
YTD -2.85%
2020 12.86%
2019 20.87%
2018 0.98%
2017 65.22%
2016 21.76%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7899 seconds.